Why It Matters
Keeping America’s Edge is pushing Congress to dramatically boost federal biomedical research funding at a critical inflection point. The organization argues that robust NIH investment is essential to maintaining American technological and economic leadership against China—framing research as a national security imperative, not merely a health policy issue.
This matters because Congress is actively debating how to compete globally in AI and emerging biotechnology while grappling with sharp declines in federal research grants and early-career scientist retention.
By the Numbers
Keeping America’s Edge is a newcomer to federal lobbying, launching advocacy efforts in mid-2025. The organization spent $680,000 across 11 disclosures in 2025, with this Q4 filing marking a $100,000 payment to Chesapeake Enterprises Inc.
The group shifted strategy mid-year, initially retaining Miller Strategies LLC ($310,000) and Venture Government Strategies LLC ($70,000) before consolidating with Chesapeake Enterprises—a veteran firm with over $14 million in total compensation history and experience representing tech giants on spectrum policy, patent reform, and defense legislation.
The Agenda
Keeping America’s Edge focuses specifically on NIH funding and protecting American research. The organization emphasizes federal support for biomedical research and scientific innovation as cornerstones of national competitiveness. The timing reflects congressional focus on U.S. technological leadership amid geopolitical competition, particularly as recent analysis suggests China is surpassing the U.S. in certain biotechnology areas.
Broader Context
Congress is actively debating American technological leadership amid concerns about falling behind China. The National Security Commission on Emerging Biotechnology released a December 2025 report assessing that China now surpasses the U.S. in certain biotechnology areas, with Chinese companies accounting for 42% of major licensing deals over $50 million in early 2025.
Meanwhile, federal research funding faces headwinds—the NIH awarded approximately 11.6% fewer grants in 2025 despite similar total funding, with early-career grant awards falling to their lowest point since 2016. However, both House and Senate appropriations committees rejected Trump’s request to significantly reduce NIH funding, maintaining funding at approximately $48 billion.
Between The Lines
Congress is intensely focused on U.S. technological competitiveness. Recent legislative efforts include H.R.5388 – American Artificial Intelligence Leadership and Uniformity Act and S.1106 – United States Leadership in Immersive Technology Act. Recent hearings like Algorithms and Authoritarians: Why U.S. AI Must Lead directly address national security implications of the technology race.
This creates significant opening for research funding advocacy, particularly when framed as national security rather than health policy.
Competitive Landscape
Keeping America’s Edge operates within a crowded advocacy ecosystem. The Technology CEO Council, Accenture, and Salesforce all lobby on AI policy and competitiveness.
However, Keeping America’s Edge occupies a distinct niche by focusing on upstream biomedical research funding rather than immediate commercialization concerns, complementing rather than competing with established tech industry efforts.
The Bottom Line
Keeping America’s Edge is lobbying at a critical moment when congressional committees have resisted NIH cuts and national security assessments warn that China is surpassing the U.S. in key biotechnology areas. By positioning biomedical research as a national security imperative, the organization is capitalizing on bipartisan concern about American innovation leadership—a framing that appears more politically durable than traditional health spending arguments.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article